<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BISMUTH SUBSALICYLATE <img border="0" src="../images/pr.gif"/></span><br/>(bis'muth)<br/><span class="topboxtradename">Pepto-Bismol<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antidiarrheal</span>; <span class="classification">salicylate</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>262 mg tablets/caplets; 130 mg/15 mL, 262 mg/15 mL, 524 mg/15 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Hydrolyzed in GI tract to salicylate, which is believed to inhibit synthesis of prostaglandins responsible for GI hypermotility
         and inflammation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness as an antidiarrheal also appears to be due to direct antimicrobial action and to an antisecretory effect on
         intestinal secretions exposed to toxins particularly of <i>Escherichia coli</i> and <i>Vibrio cholerae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of traveler's diarrhea (turista) and for temporary relief of indigestion.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>
<i>Helicobacter pylori</i> associated with peptic ulcer disease.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to aspirin or other salicylates; concurrent use with aspirin; use for more than 2 d in presence of high fever
         or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes and gout; concurrent use with salicylates and anticoagulants; pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mL or 2 tab q3060min prn (max: 8 doses/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>36 y,</i> 5 mL or ½ tab q3060min prn (max: 8 doses/d); <i>69 y,</i> 2/3 tab or 10 mL q3060 min prn (max: 8 doses/d); <i>912 y,</i> 15 mL or 1 tab q3060min prn (max: 8 doses/d)<br/><br/><span class="indicationtitle">Traveler's Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 24 tab or 1530 mL q.i.d. for 3 wk<br/><br/><span class="indicationtitle">Peptic Ulcer Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 tablets q.i.d. with 2 additional antibiotics for 1014 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10 y, 15 mL q.i.d. times 6 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure chewable tablets are chewed or crushed before being swallowed and followed with at least 8 oz water or other liquid.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Temporary <span class="speceff-common">darkening of stool</span> and tongue, metallic taste, bluish gum line; bleeding tendencies. With high doses: fecal impaction. <span class="typehead">CNS:</span> Encephalopathy (disorientation, muscle twitching). <span class="typehead">Hematologic:</span> Bleeding tendency. <span class="typehead">Special Senses:</span>  Tinnitus, hearing loss. <span class="typehead">Urogenital:</span> Incontinence. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Because bismuth subsalicylate is radiopaque, it may interfere with <span class="alt">radiographic studies</span> of GI tract.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Bismuth may decrease the absorption of <span class="classification">tetracyclines</span>, <span class="classification">quinolones</span>
<b>(ciprofloxacin,</b>
<b>norfloxacin,</b>
<b>ofloxacin).</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Undergoes chemical dissociation in GI tract to bismuth subcarbonate and sodium salicylate; bismuth is minimally absorbed,
      but the salicylate is readily absorbed. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor bowel function; note that stools may darken and tongue may appear black. These are temporary effects and will disappear
            without treatment.
         </li>
<li>Lab tests: <i>H. pylori</i> breath test when used for peptic ulcers.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Bismuth contains salicylate. Use caution when taking aspirin and other salicylates. Many OTC medications for colds, fever,
            and pain contain salicylates.
            						
         </li>
<li>Consult physician if diarrhea is accompanied by fever or continues for more than 2 d.</li>
<li>
            							Note: Temporary grayish black discoloration of tongue and stool may occur.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>